Acute leukaemia, Acute lymphoblastic leukaemia (ALL), Blood cancers, Children's cancers, Leukaemia
Results
Phase 1/2
This trial looked at selumetinib and dexamethasone for people with acute lymphoblastic leukaemia (ALL).
The trial was for adults and children with ALL that:
had come back after treatment or had continued to get worse during treatment
had a gene change () in the RAS-pathway that controls the MEK protein
This trial was supported by Cancer Research UK. People could join the trial between 2018 and 2022. The team published the results in 2026.
You pronounce selumetinib as sell-you-me-ti-nib.
Recruitment start: 17 April 2018
Recruitment end: 31 December 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Tobias Menne
AstraZeneca
Cancer Research UK
Innovative Therapies for Children with Cancer (ITCC)
Experimental Cancer Medicine Centre (ECMC)
University of Birmingham
This is Cancer Research UK trial number CRUKD/16/015.
Last reviewed: 17 Apr 2026
CRUK internal database number: 14315
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
